AnaSpec News

SensoLyte® 520 TACE (α-Secretase) Activity Assay Kit

Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice, a paper authored by Omote, K. et al. and published in the March 19th 2014 issue of American Journal of Physiology - Renal is one of the three 2014 publications citing the use of AnaSpec's SensoLyte® 520 TACE (alpha-Secretase) Activity Assay Kit to date (May 28, 2014).

The other two 2014 publications are:

Jedicke, N. et al. (2014). Alpha-1-antitrypsin inhibits acute liver failure in mice. Hepatology 59, 2299. doi: 10.1002/hep.27024.

Xu, X. et al. (2014). MUC1 in Macrophage: Contributions to Cigarette Smoke–Induced Lung Cancer. Cancer Res 74, 460. doi: 10.1158/0008-5472.CAN-13-1713.

 

To view the entire list of citations (12 times in 2013), please click here .

 

About AnaSpec's SensoLyte® 520 TACE (alpha-Secretase) Activity Assay Kit
SensoLyte® 520 TACE Activity Assay Kit uses a 5-FAM (fluorophore) and QXL® 520 (quencher) labeled FRET peptide substrate for the continuous measurement of TACE enzyme activity. In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL® 520. Upon cleavage of the FRET peptide by the active enzyme, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL® 520 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity. The kit can be used to detect the activity of TACE or screen for TACE inhibitors. The assays are performed in a convenient 96-well format. IDE FRET

 

 

  < Back